Managing the severely ill and long-term depressed

International Journal of Psychiatry in Clinical Practice

Volumn 3, Issue SUPPL. 1, 1999, Pages

  Montgomery, Stuart A ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Long term; Reboxetine; Severe depression; Suicide; Unique selective noradrenaline reuptake inhibitor (selective NRI)

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; MOCLOBEMIDE; PAROXETINE; PHENELZINE; REBOXETINE; SERTRALINE; VENLAFAXINE;

CONFERENCE PAPER; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; LONG TERM CARE; PREVALENCE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RELAPSE; SUICIDE;

EID: 0032961135     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Kessler RC, McGonagle KA, Zhao S et al (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 51: 8-19.
2. Lépine JP, Gastpar M, Mendlewicz J, Tylee A on behalf of the DEPRES Steering Committee (1997) Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 12: 19-29.
3. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
4. Nierenberg AA (1994) The treatment of severe depression: is there an efficacy gap between SSRI and TCA antidepressant generations? J Clin Psychiatry 9: 55-9.
5. American Psychiatric Association (1994) Mood disorders. In: Diagnostic and statistical manual of mental disorders. Fourth edition. APA, Washington DC.
6. Schatzberg AF (1996/1997) Treatment of severe depression with the selective serotonin reuptake inhibitors. Depression Anxiety 4: 182-9.
7. Danish University Antidepressant Group (DUAG) (1986) Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacol 90: 131-8.
8. Danish University Antidepressant Group (DUAG) (1990) Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance but weaker antidepressant effect than clomipramine in a controlled multi-center study. J Affect Dis 18: 289-99.
9. Kasper S, Fuger J, Moller HJ (1992) Comparative efficacy of antidepressants. Drugs 43: 11-23.
10. Anderson IM, Tomenson BM (1994) The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 8: 238-49.
11. Kasper S (1997) Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. J Clin Psychopharmacol 17: 10S-28S.
12. Clerc GE, Ruimy P, Verdeau-Pailles J on behalf of the Venlafaxine French Inpatient Study Group (1994) A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 9: 138-43.
13. Lopez-Ibor J, Guelfi JD, Pletan Y et al (1996) Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 11 (suppl 4): 41-6.
14. Wheatley DP, van Moffaert M, Timmerman L, Kremer CME and the mirtazapine-fluoxetine study group (1998) Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psychiatry 59: 306-12.
15. Prien RF, Kupfer DJ (1986) Continuation therapy for major depressive episodes: how long should it be maintained? Am J Psychiatry 143: 18-23.
16. Montgomery SA, Montgomery DB (1992a) Prophylactic treatment in recurrent unipolar depression. In: Perspectives in Psychiatry Vol. 3 (eds S Montgomery, F Rouillon) 53-79. Wiley, New York.
17. Montgomery SA (1994) Antidepressants in long-term treat-ment. Annu Rev Med 45: 447-57.
18. Task Force of the Collegium Internationale Neuro-Psychopharmacologicum (CINP) (1993) Impact of neuropharmacology in the 1990s-strategies for the therapy of depressive illness. Eur Neuropsychopharmacol 3: 153-6.
19. Doogan DP, Caillard V (1992) Sertraline in the prevention of depression. Br J Psychiatry 160: 217-22.
20. Montgomery SA, Dunbar G (1993) Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 8: 189-95.
21. Entsuah AR, Rudolph RL, Hackett D, Miska S (1996) Efficacy of venlafaxine and placebo during long-term treatment of depression: a pooled analysis of relapse rates. Int Clin Psychopharmacol 11: 137-45.
22. Montgomery SA (1997) Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 11: S9-S15.
23. Montgomery SA (1992) Suicide and antidepressants. Drugs 43: 24-31.
24. Kapur S, Mieczkowski T, Mann J (1992) Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA 266: 3441-5.
25. Avery D, Winokur G (1978) Suicide, attempted suicide, and relapse rates in depression. Arch Gen Psychiatry 35: 749-53.
26. Dasgupta K (1990) Additional case of suicidal ideation associated with fluoxetine. Am J Psychiatry 147: 1570.
27. Masand P, Gupta S, Dewan M (1991) Suicidal ideation related to fluoxetine treatment. N Engl J Med 324: 430.
28. Mucci M (1997) Reboxetine: a review of antidepressant tolerability. J Psychopharmacol 11: S33-S37.